Continuous Infusion in Preclinical Research
Continuous intravenous infusion is a cornerstone delivery method in preclinical pharmacology, enabling researchers to maintain stable plasma drug concentrations over extended periods without the peak-trough fluctuations inherent to bolus dosing. This is particularly important for compounds with short elimination half-lives, narrow therapeutic windows, or concentration-dependent pharmacodynamic effects where sustained exposure above a minimum effective concentration is required. In rodent studies, continuous infusion is delivered via surgically implanted jugular vein catheters connected to an external syringe pump through a tether and swivel system that allows the animal to move freely in its home cage. The infusion rate must be precisely calculated from the desired dose (mg/kg/hr), the animal's body weight, and the drug concentration in solution. Errors in this calculation — such as confusing mg/kg/hr with mg/kg/day, using the wrong body weight, or miscalculating the drug concentration after dilution — are among the most common and consequential mistakes in preclinical infusion studies, potentially leading to sub-therapeutic exposure, toxicity, or animal welfare concerns. Careful dose-to-rate conversion, verified against blood volume safety limits, is essential for every infusion study. Modern syringe pumps offer programmable rate profiles including constant rate, ramping, pulsed, and bolus-plus-maintenance modes, but the accuracy of the delivered dose ultimately depends on the accuracy of the rate calculation entered by the researcher.
Blood Volume and Safety Limits
The maximum volume that can be safely infused into a rodent is constrained by the animal's total circulating blood volume and its capacity to compensate for volume loading. Published blood volume estimates are approximately 72 mL/kg for mice and 64 mL/kg for rats, with strain-specific variation of roughly 5-10%. Regulatory and institutional guidelines, including those from the European Medicines Agency (EMA), the UK Home Office, and the National Centre for the Replacement, Refinement and Reduction of Animals in Research (NC3Rs), recommend that continuous IV infusion rates should not exceed 4 mL/kg/hr in conscious rodents for prolonged infusions (greater than 24 hours). For shorter infusion durations (less than 4 hours), rates up to 5 mL/kg/hr are generally acceptable in conscious animals, and up to 10 mL/kg/hr under anesthesia where cardiovascular monitoring is available. Exceeding these limits can cause hemodilution (reducing hematocrit and oxygen-carrying capacity), hypervolemia (increasing cardiac preload and venous pressure), pulmonary edema, and electrolyte imbalances. The practical implication is that the drug solution must be sufficiently concentrated to deliver the required dose within the allowable volume rate. When the target dose demands a flow rate that approaches blood volume limits, the drug concentration should be increased (if solubility permits) rather than the infusion rate. This tool automatically flags protocols where the calculated infusion volume rate exceeds recommended thresholds based on the animal species and body weight entered.
Dose Escalation Protocols
Dose escalation (also called dose ramping or dose titration) protocols are widely used in preclinical infusion studies for dose-response characterization, maximum tolerated dose (MTD) determination, and to allow gradual physiological adaptation to a drug's pharmacological effects. In a within-subject escalating dose design, a single animal receives progressively increasing infusion rates over sequential time intervals, with each step maintained long enough to approach or reach pharmacokinetic steady state before escalating to the next level. This design is statistically efficient because each animal serves as its own control, reducing inter-animal variability and the total number of animals required. Common escalation schemes include linear step increments (e.g., 1x, 2x, 3x, 4x the base rate), logarithmic increments (e.g., 0.1, 0.3, 1, 3, 10 mg/kg/hr), or modified Fibonacci sequences. The duration of each step depends on the drug's pharmacokinetic profile: for a drug with a 30-minute half-life, each step should last at least 2-2.5 hours (approximately 4-5 half-lives) to reach steady state, though shorter intervals of 15-30 minutes may be acceptable for acute pharmacodynamic assessments. Critical considerations include cumulative drug exposure (earlier doses contribute to plasma levels at later steps), potential for receptor desensitization or sensitization, and the need to maintain total infusion volume within blood volume safety limits even at the highest dose step. The syringe concentration is fixed, so escalation is achieved solely by increasing the pump flow rate, and the maximum dose is constrained by either the pump's maximum flow rate or the blood volume limit, whichever is reached first.
